{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:44:05Z","timestamp":1769629445553,"version":"3.49.0"},"reference-count":42,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To assess the relationship between infection risk and abatacept (ABA) exposure levels in patients with polyarticular-course juvenile idiopathic arthritis (pJIA) following treatment with subcutaneous (SC) and intravenous (IV) ABA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Data from 2 published studies (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01844518\">NCT01844518<\/jats:ext-link>,  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00095173\">NCT00095173<\/jats:ext-link>) of ABA treatment in pediatric patients were analyzed. One study treated patients aged 2\u201317 years with SC ABA and the other treated patients aged 6\u201317 years with IV ABA. Association between serum ABA exposure measures and infection was evaluated using Kaplan-Meier plots of probability of first infection vs time on treatment by ABA exposure quartiles and log-rank tests. Number of infections by ABA exposure quartiles was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Overall, 343 patients were included in this analysis: 219 patients received SC ABA and 124 patients received IV ABA. Overall, 237\/343 (69.1%) patients had \u2265 1 infection over 24 months. No significant difference in time to first infection across 4 quartiles of ABA exposure levels was observed in the pooled (<jats:italic>P<\/jats:italic> = 0.45), SC (2\u20135 yrs: <jats:italic>P<\/jats:italic> = 0.93; 6\u201317 yrs: <jats:italic>P<\/jats:italic> = 0.48), or IV (<jats:italic>P<\/jats:italic> = 0.50) analyses. Concomitant use of methotrexate and glucocorticoids (at baseline and throughout) with ABA did not increase infection risk across the ABA exposure quartiles. There was no evidence of association between number of infections and ABA exposure quartiles. No opportunistic infections related to ABA were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>In patients aged 2\u201317 years with pJIA, no evidence of association between higher levels of exposure to IV ABA or SC ABA and incidence of infection was observed.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.200154","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T13:20:13Z","timestamp":1610716813000},"page":"1073-1081","source":"Crossref","is-referenced-by-count":6,"title":["Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-0783","authenticated-orcid":false,"given":"Nikolay","family":"Tzaribachev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7637-2933","authenticated-orcid":false,"given":"Gabriel","family":"Vega-Cornejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-0217","authenticated-orcid":false,"given":"Ingrid","family":"Louw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3260-4226","authenticated-orcid":false,"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1538-744X","authenticated-orcid":false,"given":"Jason","family":"Dare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela","family":"Espada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Faugier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6101-8608","authenticated-orcid":false,"given":"Manuel","family":"Ferrandiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Gerloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-549X","authenticated-orcid":false,"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-6508","authenticated-orcid":false,"given":"Clovis Artur","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-2981","authenticated-orcid":false,"given":"Linda","family":"Wagner-Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7637-9617","authenticated-orcid":false,"given":"Yash","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-6274","authenticated-orcid":false,"given":"Julie","family":"Passarell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6562-8657","authenticated-orcid":false,"given":"Marleen","family":"Nys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-8132","authenticated-orcid":false,"given":"Robert","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-1459","authenticated-orcid":false,"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0130","authenticated-orcid":false,"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"2022062305300687000_48.7.1073.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"2022062305300687000_48.7.1073.2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/BOR.0000000000000206","article-title":"Advances in the treatment of polyarticular juvenile idiopathic arthritis","volume":"27","author":"Webb","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"2022062305300687000_48.7.1073.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"2022062305300687000_48.7.1073.4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40262-016-0497-x","article-title":"Remarkable pharmacokinetics of monoclonal antibodies: a quest for an explanation","volume":"56","author":"Reijers","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2022062305300687000_48.7.1073.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.145"},{"key":"2022062305300687000_48.7.1073.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu457"},{"key":"2022062305300687000_48.7.1073.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.11015"},{"key":"2022062305300687000_48.7.1073.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.20861"},{"key":"2022062305300687000_48.7.1073.9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","article-title":"Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries","volume":"20","author":"Swart","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022062305300687000_48.7.1073.10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2022062305300687000_48.7.1073.11","doi-asserted-by":"crossref","first-page":"e0179179","DOI":"10.1371\/journal.pone.0179179","article-title":"Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: a multicenter retrospective cohort study in Japan","volume":"12","author":"Mori","year":"2017","journal-title":"PLoS One"},{"key":"2022062305300687000_48.7.1073.12","first-page":"60","article-title":"Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology","volume":"37","author":"Carrara","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022062305300687000_48.7.1073.13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120994"},{"key":"2022062305300687000_48.7.1073.14","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.124"},{"key":"2022062305300687000_48.7.1073.15","first-page":"1","article-title":"The macrophages in rheumatic diseases","volume":"9","author":"Laria","year":"2016","journal-title":"J Inflamm Res"},{"key":"2022062305300687000_48.7.1073.16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/acr2.1034","article-title":"Safety of abatacept versus placebo in rheumatoid arthritis: integrated data analysis of nine clinical trials","volume":"1","author":"Simon","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2022062305300687000_48.7.1073.17","unstructured":"World Health Organization . Children\u2019s environmental health. [Internet. Accessed March 3, 2021]. Available from: http:\/\/www.who.int\/ceh\/risks\/en\/"},{"key":"2022062305300687000_48.7.1073.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.34458"},{"key":"2022062305300687000_48.7.1073.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"2022062305300687000_48.7.1073.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.27431"},{"key":"2022062305300687000_48.7.1073.21","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/art.39234","article-title":"Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022062305300687000_48.7.1073.22","first-page":"2272","article-title":"Long-term effectiveness and safety of abatacept in juvenile idiopathic arthritis: interim results from the abatacept in JIA registry [abstract]","volume":"69","author":"Lovell","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022062305300687000_48.7.1073.23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2022062305300687000_48.7.1073.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.074773"},{"key":"2022062305300687000_48.7.1073.25","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.188946"},{"key":"2022062305300687000_48.7.1073.26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12969-018-0261-x","article-title":"Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology","volume":"16","author":"Brunner","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"2022062305300687000_48.7.1073.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207841"},{"key":"2022062305300687000_48.7.1073.28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-020-02167-2","article-title":"Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee","volume":"22","author":"Giancane","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022062305300687000_48.7.1073.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"2022062305300687000_48.7.1073.30","doi-asserted-by":"crossref","unstructured":"Lovell D , Ruperto N , Quartier P , Paz E , Rubio-Perez N , Silva CA , Clinically meaningful improvements in health-related quality of life, pain and sleep quality in children with polyarticular juvenile idiopathic arthritis treated with abatacept over the long term. Paper presented at: American College of Rheumatology Annual Meeting; November 6-11, 2010; Atlanta, GA. Oral presentation number 1407.","DOI":"10.1186\/1546-0096-6-S1-P85"},{"key":"2022062305300687000_48.7.1073.31","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0542-z"},{"key":"2022062305300687000_48.7.1073.32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2147\/DDDT.S52099","article-title":"Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis \u2014 focus on subcutaneous tocilizumab","volume":"8","author":"Nakashima","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"2022062305300687000_48.7.1073.33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2022062305300687000_48.7.1073.34","first-page":"226","article-title":"Effect of methotrexate on the immune response in selected experimental models","volume":"58","author":"Zimecki","year":"2004","journal-title":"Postepy Hig Med Dosw"},{"key":"2022062305300687000_48.7.1073.35","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000352"},{"key":"2022062305300687000_48.7.1073.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093690"},{"key":"2022062305300687000_48.7.1073.37","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90060-S"},{"key":"2022062305300687000_48.7.1073.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.10529"},{"key":"2022062305300687000_48.7.1073.39","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J Rheumatol"},{"key":"2022062305300687000_48.7.1073.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.23913"},{"key":"2022062305300687000_48.7.1073.41","doi-asserted-by":"publisher","DOI":"10.1002\/art.34530"},{"key":"2022062305300687000_48.7.1073.42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.200154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T12:32:16Z","timestamp":1655987536000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.200154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,1]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.3899\/jrheum.200154"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.200154","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}